Hypokalemia

Abiraterone [1], hypokalemia ---> SmPC of [1] of EMA

Caution is required in treating patients whose underlying medical conditions might be compromised by hypokalaemia

Aliskiren/hydrochlorothiazide [1], hypokalemia ---> SmPC of [1] of EMA

The co-administration may increase the risk of hypokalaemia. Monitoring of potassium plasma levels is advised.

Amiodarone [1], hypokalemia ---> SmPC of [1] of eMC

Caution should be exercised over combined therapy with drugs which may also cause hypokalaemia and/or hypomagnesaemia

Amisulpride, hypokalemia

Concomitant use of amisulpride with drugs inducing hypokaliemia is not recommended

Amitriptyline, hypokalemia

Risk of hypokalemia. Concomitant use should be avoided

Amphotericin, hypokalemia

The co-administration may increase the hypokalaemic effect

Anagrelide [1], hypokalemia ---> SmPC of [1] of EMA

Caution should be taken when using anagrelide in patients with known risk factors for prolongation of the QT interval, medicinal products that can prolong QTc interval and hypokalaemia.

Arsenic trioxide [1], hypokalemia ---> SmPC of [1] of EMA

Patients who are receiving, or who have received, medicinal products known to cause hypokalemia or hypomagnesaemia, may be at higher risk for torsade de pointes.

Azithromycin [1], hypokalemia ---> SmPC of [1] of eMC

Azithromycin should be used with caution in patients currently receiving treatment with other active substances that cause electrolyte imbalance

Bambuterol, hypokalemia

Concomitant hypokalaemic treatment may potentiate the possible hypokalaemic effect of beta2-adrenergic agonists. Use with caution

Beclometasone/formoterol/glycopyrronium [1], hypokalemia ---> SmPC of [1] of EMA

Hypokalaemia may be potentiated by concomitant treatment with other medicinal products which can induce hypokalaemia, such as xanthine derivatives, steroids and diuretics

Bedaquiline [1], hypokalemia ---> SmPC of [1] of EMA

Bedaquiline treatment initiation is not recommended in patients with hypokaliemia, unless the benefits of bedaquiline are considered to outweigh the potential risks

Beta-adrenergic agonists, hypokalemia

Owing to the hypokalaemic effect of beta-agonists, co-administration of serum potassium depleting agents known to exacerbate the risk of hypokalaemia should be administered cautiously after careful evaluation of the benefits and risks

Beta2-adrenergic agonists, hypokalemia

Concomitant hypokalaemic treatment may potentiate the possible hypokalaemic effect of beta2-adrenergic agonists. Use with caution

Bisacodyl [1], hypokalemia ---> SmPC of [1] of eMC

The concomitant use of diuretics or adreno-corticosteroids may increase the risk of electrolyte imbalance if excessive doses of bisacodyl are taken.

Bumetanide, hypokalemia

The hypokalaemic effect of bumetanide can be increased by other potassium-lowering drugs

Carbenoxolone, hypokalemia

Increased risk of hypokalemia.

Cardiac glycosides, hypokalemia

The decrease of extracellular potasium concentrations enhances the arrhythmogenic effect of the cardiac glycoside

Chloral hydrate, hypokalemia

Concomitant use of chloral hydrate with drugs that can cause hypokaliemia should be avoided

Chlorpromazine [1], hypokalemia ---> SmPC of [1] of eMC

QT prolongation is exacerbated, in particular, in the presence of hypokalaemia

Chlorprothixene, hypokalemia

The co-administration of chlorprothixene with drugs that can cause hypokaliemia should be avoided

Citalopram [1], hypokalemia ---> SmPC of [1] of eMC

Caution is warranted for concomitant use of citalopram and hypokalaemia/hypomagnesaemia inducing medicinal products as these conditions increase the risk of malignant arrhythmias

Clarithromycin [1], hypokalemia ---> SmPC of [1] of eMC

Clarithromycin should not be given to patients with hypokalaemia (risk of prolongation of QT-time)

Corticosteroids, hypokalemia

Concomitant hypokalaemic treatment with methylxanthine derivatives, steroids, or non-potassium-sparing diuretics may potentiate the possible hypokalaemic effect of beta2-adrenergic agonists

Corticosteroids, hypokalemia

Concomitant hypokalaemic treatment with methylxanthine derivatives, steroids or non-potassium-sparing diuretics may potentiate the possible hypokalaemic effect of beta2-adrenergic agonists

Corticosteroids, hypokalemia ---> SmPC of [indacaterol/glycopyrronium] of EMA

Concomitant hypokalaemic treatment with methylxanthine derivatives, steroids, or non-potassium-sparing diuretics may potentiate the possible hypokalaemic effect of beta2-adrenergic agonists, therefore use with caution

Dasatinib [1], hypokalemia ---> SmPC of [1] of EMA

In vitro data suggest that dasatinib has the potential to prolong cardiac ventricular repolarisation (QT Interval). Dasatinib should be administered with caution to patients who have or may develop prolongation of QTc.

Delamanid [1], hypokalemia ---> SmPC of [1] of EMA

Treatment with delamanid should not be initiated in patients with risk factors like electrolyte disturbances, particularly hypokalaemia, hypocalcaemia or hypomagnesaemia unless the possible benefit is considered to outweigh the potential risks.

Diazoxide, hypokalemia

Increased hyperglycemic effect

Digital glycosides, hypokalemia ---> SmPC of [budesonide/formoterol] of EMA

Hypokalaemia may increase the disposition towards arrhythmias in patients who are treated with digitalis glycosides.

Digitoxin, hypokalemia

Increased effect of digitoxin and risk of digitoxin intoxication due to drug-induced hypokaliemia and hypomagnesemia

Digoxin [1], hypokalemia ---> SmPC of [1] of eMC

Agents causing hypokalaemia or intracellular potassium deficiency may cause increased sensitivity to digoxin

Dimenhydrinate, hypokalemia

The concurrent use of dimenhydrinate and drugs that can cause hypokaliemia should be avoided

Diphenhydramine, hypokalemia

The co-administration is contraindicated

Disopyramide [1], hypokalemia ---> SmPC of [1] of eMC

Concomitant use of disopyramide with drugs can induce hypokalaemia may reduce the action of the drug, or potentiate proarrhythmic effects

Dofetilide, hypokalemia

Periodic monitoring of serum potassium is recommended, when dofetilide is administered with drugs which may cause hypokaliemia

Doxepin, hypokalemia

The co-administration of doxepin with medicinal products that can cause hypokaliemia should be avoided

Doxylamine, hypokalemia

Concomitant use of doxylamine with drugs that cause electrolyte imbalance should be avoided

Dronedarone [1], hypokalemia ---> SmPC of [1] of EMA

Since antiarrhythmic medicinal products may be ineffective or may be arrhythmogenic in patients with hypokalemia, any potassium or magnesium deficiency should be corrected before initiation and during dronedarone therapy.

Droperidol [1], hypokalemia ---> SmPC of [1] of eMC

To prevent QT prolongation, caution is necessary when patients are taking medicinal products likely to induce electrolyte imbalance

Ebastine, hypokalemia

The administration should be done with caution in patients with known heart risk such as hypokaliemia

Escitalopram [1], hypokalemia ---> SmPC of [1] of eMC

Caution is warranted for concomitant use of escitalopram with hypokalaemia/hypomagnesaemia inducing medicinal products as these conditions increase the risk of malignant arrhythmias

Fesoterodine [1], hypokalemia ---> SmPC of [1] of EMA

TOVIAZ should be used with caution in patients with risk for QT prolongation (e.g. hypokalaemia, bradycardia and concomitant administration of medicines known to prolong QT interval) and relevant pre-existing cardiac diseases

Flecainide [1], hypokalemia ---> SmPC of [1] of eMC

Hypokalaemia but also hyperkalaemia or other electrolyte disturbances should be corrected before administration of flecainide. Hypokalaemia may result from the concomitant use of diuretics, corticosteroids or laxatives.

Flupentixol, hypokalemia

Drugs known to cause electrolyte disturbances such as thiazide diuretics (hypokalaemia) should also be used with caution as they may increase the risk of QT prolongation and malignant arrythmias

Fluphenazine [1], hypokalemia ---> SmPC of [1] of eMC

Electrolyte imbalance, particularly hypokalaemia, greatly increases the risk of QT interval prolongation. Therefore, concurrent use of fluphenazine and drugs that cause electrolyte imbalance should be avoided.

Fluticasone furoate/umeclidinium/vilanterol [1], hypokalemia ---> SmPC of [1] of EMA

Caution should be exercised when Trelegy Ellipta is used with other medicinal products that also have the potential to cause hypokalaemia

Formoterol [1], hypokalemia ---> SmPC of [1] of eMC

Concomitant treatment may potentiate a possible hypokalaemic effect of beta2-agonists.

Glucocorticoids, hypokalemia

Hypokalaemic effects are enhanced by corticosteroids.

Guanfacin [1], hypokalemia ---> SmPC of [1] of EMA

Guanfacine should be prescribed with caution in patients with risk factors for torsade de pointes (e.g., heart block, bradycardia, hypokalaemia) or patients who are taking medicinal products known to prolong the QT interval.

Haloperidol [1], hypokalemia ---> SmPC of [1] of eMC

Concurrent use of drugs causing electrolyte imbalance may increase the risk of ventricular arrhythmias and is not recommended. Diuretics, in particular those causing hypokalaemia, should be avoided

Hydroquinidine, hypokalemia

Concomitant use of hydroquinidine and hypokalaemic agents increases the risk of heart rhythm disorders (torsades de pointes)

Hydroxyzine, hypokalemia

Caution is recommended with bradycardia and hypopotassemia inducing medicinal products

Hypokalemia, hypokalemia

Increased risk of hypokalemia.

Hypokalemia, indacaterol [2] ---> SmPC of [2] of EMA

Concomitant hypokalaemic treatment may potentiate the possible hypokalaemic effect indacaterol. Use with caution

Hypokalemia, indacaterol/glycopyrronium [2] ---> SmPC of [2] of EMA

Concomitant hypokalaemic treatment may potentiate the possible hypokalaemic effect indacaterol. Use with caution

Hypokalemia, indapamide [2] ---> SmPC of [2] of eMC

Increased risk of hypokalaemia (additive effect).

Hypokalemia, irbesartan/hydrochlorothiazide [2] ---> SmPC of [2] of EMA

The co-administration may increase the risk of hypokalaemia. Monitoring of potassium plasma levels is advised.

Hypokalemia, josamycin

In case of hypokaliemia, the use of macrolide antibiotics is not indicated due to possible arrythmias, because they prolong the QT interval

Hypokalemia, lactitol

The co-administration of hypokaliemia-inducer drugs may enhance the potassium loss

Hypokalemia, lapatinib [2] ---> SmPC of [2] of EMA

Caution should be taken if lapatinib is administered to patients with conditions that could result in prolongation of QTc

Hypokalemia, laxatives

The co-administration of hypokaliemia-inducer drugs may enhance the potassium loss

Hypokalemia, levacetylmethadol

Medicinal products known to induce low blood salts must never be taken during the course of levacetylmethadol treatment

Hypokalemia, levomepromazine [2] ---> SmPC of [2] of eMC

Avoid concomitant neuroleptics and any other drugs that may cause electrolyte imbalance. Diuretics, in particular those causing hypokalemia, should be avoided but, if necessary, potassium-sparing diuretics are preferred.

Hypokalemia, lidocaine [2] ---> SmPC of [2] of eMC

The action of lidocaine is antagonised by hypokalaemia.

Hypokalemia, lipegfilgrastim [2] ---> SmPC of [2] of EMA

Hypokalaemia may occur. For patients with increased risk on hypokalaemia due to underling disease or co-medications, it is recommended to monitor the serum potassium level carefully and to substitute potassium if necessary.

Hypokalemia, lofepramine

The combination of lofepramine with drugs that may cause hypokalaemia may increase the risk of ventricular arrhythmias including torsades de pointes. Caution is recommended

Hypokalemia, losartan/hydrochlorothiazide [2] ---> SmPC of [2] of eMC

Periodic monitoring of serum potassium and ECG is recommended when losartan/hydrochlorothiazide is administered with hypokalaemia-inducing medicinal products, as hypokalaemia is a predisposing factor to torsades de pointes

Hypokalemia, macrolide antibiotics

In case of hypokaliemia, the use of macrolide antibiotics is not indicated due to possible arrythmias, because they prolong the QT interval

Hypokalemia, melperone

The co-administration of melperone with drugs that can cause hypokaliemia should be avoided

Hypokalemia, methadone [2] ---> SmPC of [2] of eMC

Cases of QT interval prolongation and torsade de pointes have been reported during methadone treatment, particularly at high doses (> 100 mg/d). Methadone should be administered with caution to patients at risk of development of prolonged QT interval

Hypokalemia, metildigoxin

It should be paid special attention when digitalis glycosides are combined with drugs that induce hypokaliemia

Hypokalemia, metolazone

The co-administration may increase the risk of hypokaliemia and fluid retention

Hypokalemia, mexiletine

The action of mexiletine is antagonised by hypokalaemia.

Hypokalemia, milrinone [2] ---> SmPC of [2] of eMC

Potassium loss due to excessive diuresis may predispose digitalised patients to arrhythmias.

Hypokalemia, moclobemide

The co-administration of moclobemide with medicinal products that can cause hypokaliemia should be avoided

Hypokalemia, moxifloxacin [2] ---> SmPC of [2] of eMC

Moxifloxacin should be used with caution in patients who are taking medication that can reduce potassium levels

Hypokalemia, non-potassium-sparing diuretics ---> SmPC of [indacaterol/glycopyrronium] of EMA

Concomitant hypokalaemic treatment with methylxanthine derivatives, steroids, or non-potassium-sparing diuretics may potentiate the possible hypokalaemic effect of beta2-adrenergic agonists, therefore use with caution

Hypokalemia, noradrenaline

The use of noradrenaline with drugs which may cause hypokaliemia is not recommended because severe, prolonged hypertension and possible arrhythmias may result

Hypokalemia, norepinephrine

The use of noradrenaline with drugs which may cause hypokaliemia is not recommended because severe, prolonged hypertension and possible arrhythmias may result

Hypokalemia, nortriptyline

The co-administration of nortriptyline with drugs that can cause hypokaliemia should be avoided

Hypokalemia, ofloxacin [2] ---> SmPC of [2] of eMC

Caution should be taken when using fluoroquinolones, including ofloxacin, in patients with known risk factors for prolongation of the QT interval such as, for example uncorrected electrolyte imbalance (e.g. hypokalaemia, hypomagnesaemia)

Hypokalemia, opipramol

Risk of hypokaliemia. Concomitant use should be avoided

Hypokalemia, perazine

The co-administration of perazine with drugs that can cause hypokaliemia should be avoided

Hypokalemia, perphenazine

Concomitant use of perphenazine with drugs causing electrolyte imbalance is not recommended.

Hypokalemia, pimozide

The co-administration of pimozide with medicinal products that cause hypokaliemia should be avoided

Hypokalemia, pipamperone

The co-administration of pipamperone with medicinal products that cause hypokaliemia should be avoided

Hypokalemia, piretanide

An electrolyte imbalance may increase the risk of arrythmias.

Hypokalemia, posaconazole [2] ---> SmPC of [2] of EMA

Electrolyte disturbances should be monitored and corrected as necessary before and during posaconazole therapy.

Hypokalemia, potassium-sparing diuretics

Concomitant hypokalaemic treatment with methylxanthine derivatives, steroids or non-potassium-sparing diuretics may potentiate the possible hypokalaemic effect of beta2-adrenergic agonists

Hypokalemia, potassium-sparing diuretics ---> SmPC of [glycopyrronium/indacaterol/mometasone] of EMA

Concomitant hypokalaemic treatment with methylxanthine derivatives, steroids, or non-potassium-sparing diuretics may potentiate the possible hypokalaemic effect of beta2-adrenergic agonists

Hypokalemia, prednisolone

The co-administration may increase the risk of hypokalaemia.

Hypokalemia, promazine

Diuretics, in particular those causing hypokalemia, should be avoided but, if necessary, potassium-sparing diuretics are preferred.

Hypokalemia, promethazine

The co-administration of promethazine with drugs that may cause hypokaliemia should be avoided

Hypokalemia, prothipendyl

Concomitant use of prothipendyl with drugs that can cause hypokaliemia should be avoided

Hypokalemia, quinidine

The cardiac toxicity of quinidine is increased if hypokalaemia occurs.

Hypokalemia, quinolones ---> SmPC of [ofloxacin] of eMC

Caution should be taken when using fluoroquinolones, including ofloxacin, in patients with known risk factors for prolongation of the QT interval such as, for example uncorrected electrolyte imbalance (e.g. hypokalaemia, hypomagnesaemia)

Hypokalemia, risperidone [2] ---> SmPC of [2] of eMC

Caution is advised when prescribing risperidone with medicines causing electrolyte imbalance

Hypokalemia, ritodrine

Possible hypokaliemia

Hypokalemia, roxithromycin

Caution is warranted for concomitant use of roxitromycin with hypokaliemia or hypomagnesemia

Hypokalemia, salbutamol

The co-administration may enhance a hypokaliemia

Hypokalemia, salmeterol [2] ---> SmPC of [2] of eMC

Owing to the hypokalaemic effect of beta-agonists, co-administration of serum potassium depleting agents known to exacerbate the risk of hypokalaemia should be administered cautiously after careful evaluation of the benefits and risks

Hypokalemia, salmeterol/fluticasone propionate [2] ---> SmPC of [2] of EMA

Aerivio Spiromax should be used with uncorrected hypokalaemia or patients predisposed to low levels of serum potassium.

Hypokalemia, selpercatinib [2] ---> SmPC of [2] of EMA

Hypokalaemia, hypomagnesaemia and hypocalcaemia should be corrected prior to initiating selpercatinib and during treatment.

Hypokalemia, senna

The co-administration of hypokaliemia-inducer drugs may enhance the potassium loss

Hypokalemia, sodium picosulfate [2] ---> SmPC of [2] of eMC

The concomitant use may increase the risk of electrolyte imbalance if excessive doses of picosulfate are taken.

Hypokalemia, sorafenib [2] ---> SmPC of [2] of EMA

Sorafenib has been shown to prolong the QT/QTc interval, which may lead to an increased risk for ventricular arrhythmias. Use sorafenib with caution in patients who have, or may develop prolongation of QTc

Hypokalemia, sotalol [2] ---> SmPC of [2] of eMC

With potassium-depleting diuretic may occur hypokalaemia or hypomagnesaemia, increasing the potential for torsade de pointes

Hypokalemia, spiramycin

In case of hypokaliemia, the use of macrolide antibiotics is not indicated due to possible arrythmias, because they prolong the QT interval

Hypokalemia, sterculia

The co-administration may cause electrolyte imbalance

Hypokalemia, sulpiride [2] ---> SmPC of [2] of eMC

The combination of sulpiride with hypokaliemia-inducing medications is not recommended

Hypokalemia, telmisartan/hydrochlorothiazide [2] ---> SmPC of [2] of EMA

Medicinal products associated with potassium loss and hypokalaemia: These medicinal products may potentiate the effect of hydrochlorothiazide on serum potassium

Hypokalemia, terbutaline [2] ---> SmPC of [2] of eMC

Potentially serious hypokalaemia may result from beta2-agonist therapy. The hypokalaemic effect may be potentiated by concomitant treatments. It is recommended that serum potassium levels are monitored in such situations.

Hypokalemia, terfenadine

Hypokalaemia or other electrolyte imbalance increases the risk of ventricular arrhythmias with terfenadine.

Hypokalemia, terlipressin

Terlipressin can cause ventricular arrhythmias. The combination with drugs that can origin electrolyte disorders should be done with extreme caution

Hypokalemia, tetracosactide

Increase of tetracosactide potassium elimination

Hypokalemia, thioridazine

Hypokalaemia increases the risk of ventricular arrhythmias with thioridazine, therefore, concomitant use should be avoided.

Hypokalemia, tiapride

Hypokaliemia-inducing medicinal products increase the risk of ventricular arrhythmias, particularly torsades de pointes. The combination is not recommended

Hypokalemia, tolterodine [2] ---> SmPC of [2] of eMC

Tolterodine should be used with caution in patients with risk factors for QT-prolongation

Hypokalemia, triamcinolone acetonide

Patients should be observed for hypokalaemia.

Hypokalemia, triamcinolone [2] ---> SmPC of [2] of eMC

Patients should be observed for hypokalaemia.

Hypokalemia, trimipramine

Increased hypokalaemic effects

Hypokalemia, umeclidinium/vilanterol [2] ---> SmPC of [2] of EMA

Concomitant hypokalaemic treatment may potentiate the possible hypokalaemic effect of beta2-adrenergic agonists. Use with caution

Hypokalemia, vardenafil [2] ---> SmPC of [2] of EMA

Medicinal products that may prolong QTc interval, including vardenafil, are best avoided in patients with relevant risk factors, for example, hypokalaemia

Hypokalemia, vasoconstrictors

A hypokaliemia may enhance the reactivity of arteries to vasoconstrictor agent, cause vasoconstriction and increase the peripheral resistance

Hypokalemia, vasodilators

A hypokaliemia may attenuate the response to the vasodilator

Hypokalemia, vilanterol

Concomitant hypokalaemic treatment may potentiate the possible hypokalaemic effect of beta2-adrenergic agonists. Use with caution

Hypokalemia, xanthines

Concomitant hypokalaemic treatment with methylxanthine derivatives, steroids, or non-potassium-sparing diuretics may potentiate the possible hypokalaemic effect of beta2-adrenergic agonists

Hypokalemia, xanthines

Concomitant hypokalaemic treatment with methylxanthine derivatives, steroids or non-potassium-sparing diuretics may potentiate the possible hypokalaemic effect of beta2-adrenergic agonists

Hypokalemia, xanthines ---> SmPC of [indacaterol/glycopyrronium] of EMA

Concomitant hypokalaemic treatment with methylxanthine derivatives, steroids, or non-potassium-sparing diuretics may potentiate the possible hypokalaemic effect of beta2-adrenergic agonists, therefore use with caution

Hypokalemia, xipamide [2] ---> SmPC of [2] of eMC

Concomitant use with xipamide may provoke hypokalaemia.

Hypokalemia, zuclopenthixol [2] ---> SmPC of [2] of eMC

Drugs known to cause electrolyte disturbances such as thiazide diuretics (hypokalemia) should be used with caution as they may increase the risk of QT prolongation and malignant arrhythmias